Neumora Therapeutics, Inc. (NMRA)
(Delayed Data from NSDQ)
$10.00 USD
+0.11 (1.11%)
Updated Jun 12, 2024 04:00 PM ET
After-Market: $10.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NMRA 10.00 +0.11(1.11%)
Will NMRA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for NMRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NMRA
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
NMRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick
Other News for NMRA
Analysts Are Bullish on These Healthcare Stocks: Halozyme (HALO), 4D Molecular Therapeutics (FDMT)
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Neumora initiates Phase 2 study of navacaprant in bipolar depression
Neumora Therapeutics, Inc. (NMRA) Gets a Buy from Bank of America Securities
Analysts Are Bullish on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), IDEAYA Biosciences (IDYA)